DDIAS may be a potential therapeutic target for tamoxifen-resistant breast cancer since the inhibition of PSPC1 or SCFD2 reduces in vivo tumor development in tamoxifen-resistant breast cancer. Here, SCFD2 is linked to breast carcinoma.